Hayti Dental Clinic | |
109 E 5th St Caruthersville MO 63830-1417 | |
(573) 922-6097 | |
Not Available |
Full Name | Hayti Dental Clinic |
---|---|
Speciality | Dentist - General Practice |
Location | 109 E 5th St, Caruthersville, Missouri |
Authorized Official Name and Position | Christopher Jones (CEO) |
Authorized Official Contact | 5737482404 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Hayti Dental Clinic 420 Semo Dr P O Box 400 New Madrid MO 63869-1734 Ph: (573) 748-2404 | Hayti Dental Clinic 109 E 5th St Caruthersville MO 63830-1417 Ph: (573) 922-6097 |
NPI Number | 1053700435 |
---|---|
Provider Enumeration Date | 01/22/2015 |
Last Update Date | 05/10/2018 |
Identifier | Type | State | Issuer |
---|---|---|---|
1053700435 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1223G0001X | Dentist - General Practice | (* (Not Available)) | Primary |
News Archive
A meta-analysis of 10 studies suggests that receipt of a blood transfusion among patients with myocardial infarction (heart attack) was associated with increased all-cause mortality compared with not receiving a blood transfusion during heart attack, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.
A rise in negative health behaviours - such as lack of sleep, exercise and an unhealthy diet - is connected to poorer mental health during the tightest restrictions of Scotland's COVID-19 lockdown, a new study has confirmed.
Both mother and fetus are at increased risk for complications of flu infection during pregnancy. And prenatal care providers say they're advising women to get the flu vaccine, in line with recommendations from various organizations. But many pregnant women don't understand the importance of this advice-and don't get the vaccine.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points.
› Verified 2 days ago